| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e78a3b54e5578a16e282d10d07797512 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5089 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2016-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dff58e4388b9f5c68151e682e9a293b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96524bde57ce43e782d967d2a9acd165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2a6bd550379d9f7cad0df4cab6f7727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbe8670fca71992bd77b2da0c572a572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fd0e4139cdb74ddda054896cf9ff5e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_995a49d0e68088839aa657cb677bdcb5 |
| publicationDate |
2016-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016331752-A1 |
| titleOfInvention |
Risperidone sustained release microsphere composition |
| abstract |
A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage. |
| priorityDate |
2011-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |